High frequency of BRAF mutations in nevi
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
To evaluate the timing of mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) during melanocytic neoplasia, we carried out mutation analysis on microdissected melanoma and nevi samples. We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi. These data suggest that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, the BRAF oncogenic mutation found in more than half of all malignant cutaneous melanomas is commonly found also in non-malignant nevi, where it causes oncogene-induced senescence exemplified by high levels of CDKN2A and SA-β-gal expression225–227.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [226]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Busca, R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.2900 · Cited by 326
The Regulation of Normal Melanocyte Proliferation
Halaban, R. (2000) · Pigment Cell Research · doi:10.1034/j.1600-0749.2000.130103.x · Cited by 179
Research works printed but not linked: 2
- Armstrong, B.K. & English, D.R. in Cancer Epidemiology and Prevention (Oxford University Press, New York, 1996).
- Elder, D.E. & Murphy, G.F. in Atlas of Tumor Pathology: Melanocytic Tumors of the Skin 5–101 (Armed Forces Insititute of Pathology, Washington, DC, 1991).
Cited by
Items 901–1,000 of 1,001
Squaring the circle: circRNAs in melanoma
Mecozzi, N., Vera, O., & Karreth, F. A. (2021) · Oncogene · doi:10.1038/s41388-021-01977-1 · Cited by 22
Melanocytic Naevi and Melanoma
Newton‐Bishop, J. (2011) · Wiley eBooks · doi:10.1002/9781444345384.ch109 · Cited by 22
Insights into Liposomal and Gel-Based Formulations for Dermatological Treatments
Strazzabosco, G., Liboni, A., Pezzi, G., Alogna, A., & Bortolotti, D. (2025) · Gels · doi:10.3390/gels11040245 · Cited by 31
“Mutant BRAF genes are commonly expressed in a majority of melanomas, indicating their significant role in melanocyte biology and disease pathology [144].”
The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms
Pinczewski, J., & Slominski, A. (2010) · Experimental Dermatology · doi:10.1111/j.1600-0625.2010.01169.x · Cited by 20
BRAF Modulates Lipid Use and Accumulation
Turner, J. A., Paton, E. L., Gulick, R. J. V., Stefanoni, D., Cendali, F. I., Reisz, J. A., Tobin, R. P., McCarter, M. D., D’Alessandro, A., Torres, R. M., et al. (2022) · Cancers · doi:10.3390/cancers14092110 · Cited by 28
Oncogenic BRAF induces whole-genome doubling through suppression of cytokinesis
Darp, R., Vittoria, M. A., Ganem, N. J., & Ceol, C. J. (2022) · Nature Communications · doi:10.1038/s41467-022-31899-9 · Cited by 22
BRAF and GNAQ mutations in melanocytic tumors of the oral cavity
Cohen, Y., Goldenberg‐Cohen, N., Akrish, S. J., Shani, T., Amariglio, N., Dratviman‐Storobinsky, O., Kaplan, I., Barshack, I., & Hirshberg, A. (2012) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2012.09.001 · Cited by 22
Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-RafV600E kinase
Wenglowsky, S., Ren, L. M., Grina, J. A., Hansen, J. D., Laird, E. R., Moreno, D., Dinkel, V., Gloor, S. L., Hastings, G. A., Rana, S., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.03.007 · Cited by 21
Opposing functions of PLAG1 in pleomorphic adenoma: a microarray analysis of PLAG1 transgenic mice
Wang, Y., Shang, W., Lei, X., Shen, S., Zhang, H., Wang, Z., Huang, L. H., Yu, Z., Ong, H., Yin, X., et al. (2013) · Biotechnology Letters · doi:10.1007/s10529-013-1213-7 · Cited by 21
Narrowing the knowledge gaps for melanoma
Slipicevic, A., & Herlyn, M. (2012) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.658977 · Cited by 25
“BRAF V600E mutations are found in 60% of benign nevi and are thought to result in the initial increase in proliferation of melanocytic cells followed by induction of cell cycle arrest and senescence (29).”
BackgroundBiologically distinct subsets of nevi.
Rogers, T., Marino, M. L., Raciti, P., Jain, M., BUSAM, K. J., Marchetti, M. A., & Marghoob, A. A. (2016) · PubMed · Cited by 22
Reevaluation of established and new criteria in differential diagnosis of Spitz nevus and melanoma
Ritter, A. M., Tronnier, M., Vaske, B., & Mitteldorf, C. (2018) · Archives of Dermatological Research · doi:10.1007/s00403-018-1818-8 · Cited by 21
Melanoma genomics: a state‐of‐the‐art review of practical clinical applications*
Guhan, S. M., Klebanov, N., & Tsao, H. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20421 · Cited by 24
Muse, M. E., Bergman, D. T., Salas, L. A., Tom, L. N., Tan, J. M., Laino, A. M., Lambie, D., Sturm, R. A., Schaider, H., Soyer, H. P., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.11.025 · Cited by 21
Self-citationId1 delays senescence of primary human melanocytes
Cummings, S. D., Ryu, B., Samuels, M. A., Yu, X., Meeker, A. K., Healey, M. A., & Alani, R. M. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20422 · Cited by 26
“BRAF kinase [23] were also shown to display evidence of cellular senescence associated with heterogeneous elevated expression of p16/INK4a [21,22].”
BackgroundBurger, M., Denzinger, S., Hammerschmied, C. G., Tannapfel, A., Maderstorfer, A., Wieland, W. F., Hartmann, A., & Stoehr, R. (2006) · European Urology · doi:10.1016/j.eururo.2005.11.031 · Cited by 21
Oncogenes as Novel Targets for Cancer Therapy (Part IV): Regulators of the Cell Cycle and Apoptosis
Zhang, Z., Li, M., Rayburn, E. R., Hill, D. L., Zhang, R., & Wang, H. (2005) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200505060-00006 · Cited by 22
NTRK Gene Fusion Detection in Atypical Spitz Tumors
Cappellesso, R., Nozzoli, F., Marino, F. Z., Simi, S., Castiglione, F., GIORGI, V. D., Cota, C., Senetta, R., Scognamiglio, G., Anniciello, A. M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212332 · Cited by 20
Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers
Gracia-Hernandez, M., Munoz, Z., & Villagra, A. (2021) · Cancers · doi:10.3390/cancers13246180 · Cited by 24
“However, this point mutation is essential for melanoma development in the nevi, which is a critical step for initiating melanocytic neoplasia [19,21,23,24].”
BackgroundUveal Melanoma Patient-Derived Xenografts
Carita, G., Némati, F., & Decaudin, D. (2015) · Ocular Oncology and Pathology · doi:10.1159/000370154 · Cited by 20
Kakavand, H., Crainic, O., Lum, T., O'Toole, S. A., Kefford, R. F., Thompson, J. F., Wilmott, J. S., Long, G. V., & Scolyer, R. A. (2014) · Pathology · doi:10.1097/pat.0000000000000077 · Cited by 20
“This suggests that the BRAF mutation rate in common acquired naevi may be lower than the initially reported rate of 82%.(7) More recent studies of small numbers of naevi have also reported lower BRAF mutation rates.”
ResultMolecular pathways supporting the proliferation staging of malignant melanoma (Review)
Pierard (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000232 · Cited by 23
Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma
Tomei, S., Wang, E., Delogu, L. G., Marincola, F. M., & Bedognetti, D. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.890586 · Cited by 22
“Among them, about 90% of mutation are represented by the valine to glutamic acid substitution (V600E) [5,6], associated with a 400-fold increased activity of the protein [8,9].”
BackgroundAn update on molecular alterations in melanocytic tumors with emphasis on Spitzoid lesions
Dimonitsas, E., Liakea, A., Sakellariou, S., Thymara, I., Giannopoulos, A., Stratigos, A., Soura, E., Saetta, A. A., & Korkolopoulou, P. A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.05.23 · Cited by 24
“In common nevi, BRAF and NRAS mutation are present in 60–87.5% and 20% of cases, respectively (8).”
InfluentialKRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K–MAPK1 inhibition
Janardhan, H. P., Meng, X., Dresser, K., Hutchinson, L., & Trivedi, C. M. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20192205 · Cited by 22
Christofyllakis, K., Pföhler, C., Bewarder, M., Müller, F. M., Thurner, L., Rixecker, T. M., VOGT, T. M., Stilgenbauer, S., Yordanova, K., & Kaddu‐Mulindwa, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.637161 · Cited by 22
“This contradiction could be explained through the fact that, while BRAF mutations are early events in their evolution (29), metastatic melanomas accumulate further genomic alterations such as whole-genome duplication over time, which may account for resistance to treatment (30).”
BackgroundTargeted therapy for metastatic melanoma.
Amaravadi, R. K., & Flaherty, K. T. (2007) · PubMed · Cited by 21
Obesity and melanoma: Exploring molecular links
Chen, J., Chi, M., Chen, C., & Zhang, X. D. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24549 · Cited by 22
“Mutation of NRAS is also common in melanoma, with frequencies estimated at50–60% [Demunter et al., 2001; Davies et al., 2002; Pollock et al., 2003].”
Kirschner, M., Helmke, B. M., Starz, H., Benner, A., Thome, M., & Deichmann, M. (2005) · Melanoma Research · doi:10.1097/00008390-200510000-00011 · Cited by 20
Low Incidence of Oncogenic EGFR, HRAS, and KRAS Mutations in Seborrheic Keratosis
Georgieva, I. A., Mauerer, A., Groesser, L., Herschberger, E., Aslanidis, C., Dietmaier, W., Landthaler, M., & Hafner, C. M. (2013) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e31828c0542 · Cited by 21
“Oncogenic BRAF mutations, for example, are found both in benign melanocytic nevi and in malignant melanoma.(29,30) Although some melanocytic nevi may show a progression to malignant melanoma, most will remain benign because of oncogene-induced senescence.”
BackgroundDMBT1 expression distinguishes anorectal from cutaneous melanoma
Helmke, B. M., Renner, M., Poustka, A., Schirmacher, P., Mollenhauer, J., & Kern, M. A. (2009) · Histopathology · doi:10.1111/j.1365-2559.2008.03200.x · Cited by 20
Rübben, A., Bausch, B., & Nikkels, A. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-36 · Cited by 20
MALDI-TOF MS: a platform technology for genetic discovery
van den Boom, D., Beaulieu, M., Oeth, P., Roth, R., Honisch, C., Nelson, M. R., Jurinke, C., & Cantor, C. R. (2004) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2004.03.015 · Cited by 20
Ponti, G., Venesio, T., Losi, L., Pellacani, G., Bertario, L., Sala, P., Pedroni, M., Petti, C., Maffei, S., Varesco, L., et al. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700723 · Cited by 20
“As BRAF mutations were identified in the sporadic melanoma and also in a large majority of precancerous skin lesions (especially in cutaneous nevi) (Pollock et al., 2003), we have investigated sebaceous hyperplasias for BRAF, N-Ras, and K-Ras mutations, an additional component of the mitogen-activated protein kinase-s…”
BackgroundThe complex management of atypical Spitz tumours
Massi, D., GIORGI, V. D., & Mandalà, M. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.003 · Cited by 20
Smalley, K. S. M., & Herlyn, M. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23430.x · Cited by 20
“In particular, a number of papers have shown that BRAF mutations are prevalent in unsuspicious benign nevi (although at levels which range from 21% to 80%)”
BackgroundPoetsch, M., Dittberner, T., & Woenckhaus, C. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-2324-4 · Cited by 20
Thompson, E. L., Hu, J., & Niedernhofer, L. J. (2021) · Cancers · doi:10.3390/cancers13092241 · Cited by 20
“The BRAFV600E mutation is often found in benign and dysplastic nevi and these nevi typically remain in growth arrest for decades without advancing to malignancy [15,38].”
BackgroundBoosting Antitumor Immunity with an Expanded Neoepitope Landscape
Nagel, R., Pataskar, A., Champagne, J., & Agami, R. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1525 · Cited by 26
“Similarly, a very specific oncogenic BRAFmutation is found in the majority of malignant melanomas, and in smaller proportions of other cancers (39).”
BackgroundGrowth Factors and Oncogenes as Targets in Melanoma: Lost in Translation?
Kwong, L. N., Chin, L., & Wagner, S. N. (2007) · Advances in Dermatology · doi:10.1016/j.yadr.2007.07.015 · Cited by 20
Uribe, P., Wistuba, I. I., & González, S. (2009) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e318185d205 · Cited by 19
“Activating mutations, especially V600E in BRAF, have been found in a high proportion of melanomas (56%– 66%), atypical nevi (52%–80%), and common nevi (73%– 82%).(9,29,30) This mutation (T1799A or V600E) is not related with CC-TT or C-T changes associated with UV light exposure.”
BackgroundMalignant Melanoma–a Genetic Overview
Bloethner, S., Scherer, D., Drechsel, M., Hemminki, K., & Kumar, R. (2009) · Actas Dermo-Sifiliográficas · doi:10.1016/s0001-7310(09)73167-9 · Cited by 23
cAMP-mediated regulation of melanocyte genomic instability: A melanoma-preventive strategy
Holcomb, N., Bautista, R., Jarrett, S. G., Carter, K. M., Krentz, M., & D'Orazio, J. A. (2018) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2018.10.008 · Cited by 22
Ohnishi, K., Nakayama, K., Ishikawa, M., Ishibashi, T., Yamashita, H., Nakamura, K., Minamoto, T., Iida, K., Razia, S., Ishikawa, N., et al. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05638-8 · Cited by 23
Proliferation Arrest in B-Raf Mutant Melanoma Cell Lines upon MAPK Pathway Activation
Houben, R., Ortmann, S., Drasche, A., Troppmair, J., Herold, M. J., & Becker, J. C. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.214 · Cited by 20
“For example, activating B-Raf mutations, which are noted in approximately 50% of human melanoma, are also present in the majority of nevi (Pollock et al., 2003), that is, benign melanocytic tumors.”
BackgroundTrauma as Triggering Factor for Development of Melanocytic Nevi
Navarini, A. A., Kolm, I., Calvo, X., Kamarashev, J. A., Kerl, K., Conrad, C., French, L. E., & Braun, R. P. (2010) · Dermatology · doi:10.1159/000276983 · Cited by 19
Cockburn, M., Hamilton, A. S., & Mack, T. M. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0273 · Cited by 19
“But it is unclear if nevi are a part of the developmental pathway for melanoma, markers of another relevant exposure (UV radiation), or reflect a genetic susceptibility in common with melanoma (6).”
BackgroundMarrot, L., Belaïdi, J.-P., Jones, C., Perez, P., & Meunier, J.-R. (2005) · Photochemistry and Photobiology · doi:10.1562/2004-10-13-ra-343.1 · Cited by 19
“found in 66% of melanoma tumors tested (29), and one specific mutation was shown to be expressed at a high frequency in nevi (30).”
BackgroundLade‐Keller, J., Kristensen, L. S., Riber‐Hansen, R., Guldberg, P., Hansen, L. L., Steiniche, T., & Hager, H. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201483 · Cited by 18
Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors
Ramurthy, S., Aikawa, M., Amiri, P., Costales, A., Hashash, A., Jansen, J. M., Lin, S. Y., Ma, S., Renhowe, P. A., Shafer, C. M., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.04.023 · Cited by 18
Prognostic factors for melanoma progression and metastasis: from Hematoxylin-Eosin to genetics.
Fernández‐Flores, A. (2012) · PubMed · Cited by 21
Silva, J. M., Deuker, M. M., Baguley, B. C., & McMahon, M. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12586 · Cited by 28
“%) mutations are also present at a high frequency in pigmented nevi; however, these melanocytic lesions are generally benign, rarely progress to melanoma, and display hallmarks of a senescence-like growth arrest (Michaloglou et al., 2005; Mooi and Peeper, 2006; Pollock et al., 2003).”
BackgroundAS1411-functionalized delivery nanosystems for targeted cancer therapy
Kozani, P. S., Kozani, P. S., & Malik, M. T. (2021) · Exploration of Medicine · doi:10.37349/emed.2021.00039 · Cited by 24
“significantly influenced by the expression of the mutant forms of the BRAF gene, such as BRAFV599E, and the activation of the RAS/RAS/MAPK pathway which happens to be essential for melanoma cell viability and transformation [99].”
BackgroundGenotyping of cutaneous melanoma.
Glitza, I. C., & Davies, M. A. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.03.01 · Cited by 22
“Interestingly, BRAF mutations are also found in up to 82% of benign nevi (26,27).”
BackgroundTargeted agents for the treatment of metastatic melanoma
Dancey, J. E., & Monzon (2012) · OncoTargets and Therapy · doi:10.2147/ott.s21259 · Cited by 18
“Constitutive activation of BRAF and the MAPK pathway impart a proliferative and survival advantage to the cancer cell.(27) Mutations in ARAF and CRAF have not been found in melanoma.”
Kaplon, J., Cornelia, H.-H., Gao, L. Y., Meissl, K., Verdegaal, E. M. E., van der Burg, S. H., van Doorn, R., & Peeper, D. S. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12248 · Cited by 21
“…amplification of CCND1 or CDK4 (Curtin et al., 2005; Kamb et al., 1994), alterations in MMP8, GRM3, ERBB4, GRIN2A, MITF (Garraway et al., 2005; Palavalli et al., 2009; Prickett et al., 2009, 2011; Wei et al., 2011; Yokoyama et al., 2011), and activation of the PI3K pathway (Stahl et al., 2004).”
BackgroundHoffmann, M., Koelsche, C., Seiz‐Rosenhagen, M., Mai, S., Lohr, F., Reuß, D., Wenz, F. K., Gebhardt, C., & Giordano, F. A. (2015) · Journal of neurosurgery · doi:10.3171/2015.5.jns15233 · Cited by 18
On Naevi and Melanomas: Two Sides of the Same Coin?
Lee, K., Janda, M., Stark, M. S., Sturm, R. A., & Soyer, H. P. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.635316 · Cited by 21
“Mechanisms/Drivers of Benign Neoplasms, Malignancy, and Metastasis The activation of the MAPK pathway is the first, essential step for melanocytic proliferation, but it is not sufficient for full malignant transformation (61).”
BackgroundSelf-citationThe Role of Sumoylation in Senescence
Scurr, L. L., Haferkamp, S., & Rizos, H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-50044-7_13 · Cited by 22
“Likewise, human naevi (moles) are benign tumors of melanocytes that frequently harbour oncogenic mutations in B-RAF ( Pollock et al., 2003 ), a protein kinase and”
BackgroundPappa, K. I., Vlachos, G. D., Roubelakis, M. G., Vlachos, D., Kalafati, T. G., Loutradis, D., & Anagnou, N. P. (2015) · BioMed Research International · doi:10.1155/2015/303791 · Cited by 19
“to represent early events in melanocyte transformation with BRAFmutations occurring as early as in benign premalignant nevi [11].”
BackgroundSullivan, R. J., & Atkins, M. B. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.504709 · Cited by 19
“Approximately 70 -- 80% of acquired melanocytic nevi and 50 -- 70% of melanomas contain a B-Raf mutation, largely confined to a specific point within the genome, designated V600E (B-Raf) [32,33].”
BackgroundGoh, A., Ramlogan‐Steel, C. A., Jenkins, K. S., Steel, J. C., & Layton, C. J. (2020) · Neoplasma · doi:10.4149/neo_2020_190815n768 · Cited by 18
T1799A BRAF Mutation is Common in PUVA Lentigines
Lassacher, A., Worda, M., Kaddu, S., Heitzer, E., Legat, F. J., Massone, C., Cerroni, L., Kerl, H., Ananthaswamy, H. N., & Wolf, P. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700250 · Cited by 18
Tetzlaff, M. T., LiVolsi, V. A., & Baloch, Z. W. (2006) · Advances in Anatomic Pathology · doi:10.1097/01.pap.0000213044.23823.d3 · Cited by 19
Cutaneous head and neck melanoma: the old and the new
Rigual, N., Popat, S. R., Jayaprakash, V., Jaggernauth, W., & Wong, M. K. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.3.403 · Cited by 18
Invasive skin carcinoma—Ras and α6β4 integrin lead the way
Mercurio, A. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00049-7 · Cited by 18
Kiszner, G., Wichmann, B., Németh, I. B., Varga, E., Meggyesházi, N., Teleki, I., Balla, P., Maros, M. E., Penksza, K., & Krenács, T. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-014-1570-1 · Cited by 17
The Biology of Classic Hairy Cell Leukemia
Bohn, J., Salcher, S., Pircher, A., Untergasser, G., & Wolf, D. G. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157780 · Cited by 17
“Provocatively, more than 80% of benign naevi of the skin already carry oncogenic BRAF mutations while never experiencing malignant transformation [25].”
BackgroundFeichtenschlager, V., Chen, L.-N., Zheng, Y. J., Ho, W. W.-S., Sanlorenzo, M., Vujic, I., Fewings, E., Lee, A., Chen, C., Callanan, C., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01955-7 · Cited by 24
The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase
Ren, L. M., Ahrendt, K. A., Grina, J. A., Laird, E. R., Buckmelter, A. J., Hansen, J. D., Newhouse, B., Moreno, D., Wenglowsky, S., Dinkel, V., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.04.015 · Cited by 17
Machnicki, M. M., Głodkowska‐Mrówka, E., Lewandowski, T., Płoski, R., Wlodarski, P. K., & Stokłosa, T. (2013) · Acta Biochimica Polonica · doi:10.18388/abp.2013_1951 · Cited by 17
“…accepted that oncogenic BRAF is incapable of driving tumorigenesis alone (Michaloglou et al., 2005) and mutations are frequently observed in benign skin lesions (Pollock et al., 2003), tumors harbouring BRAF mutation are highly dependent on its effects (Hingorani et al., 2003; Solit et al., 2006).”
BackgroundRyu, B., Moriarty, W. F., Stine, M. J., DeLuca, A. M., Kim, D. S., Meeker, A. K., Grills, L. D., Switzer, R. A., Eller, M. S., & Alani, R. M. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.65 · Cited by 17
“It has been implicated as a critical mediator of melanoma development, with the V600E activating mutation representing the most commonly mutated form of BRAF in nevi and melanomas (Pollock et al., 2003).”
Identification ofBRAFmutations in eruptive melanocytic nevi: new insights into melanomagenesis?
John, J. K., & Smalley, K. S. M. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.30 · Cited by 19
Scheier, B. Y., Amaria, R. N., Lewis, K. D., & Gonzalez, R. C. (2011) · Immunotherapy · doi:10.2217/imt.11.136 · Cited by 17
p15 Expression Differentiates Nevus from Melanoma
Taylor, L. A., O'Day, C., Dentchev, T., Hood, K., Chu, E. Y., Ridky, T. W., & Seykora, J. T. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.08.009 · Cited by 17
“However, the presence of BRAF mutations in 82% of nevi indicates that such a mutation alone is insufficient for conferring malignancy.(5) Clinically, most nevi grow until they reach 3 to 5 mm, at which time nevomelanocytes typically exit the proliferative growth phase and enter a state of growth arrest.”
BackgroundMelanoma asociado a nevo melanocítico
Martín-Gorgojo, A., & Nagore, E. (2017) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2017.06.009 · Cited by 22
Kfir-Elirachman, K., Ortenberg, R., Vizel, B., Besser, M. J., Barshack, I., Schachter, J., Nemlich, Y., & Markel, G. (2018) · Neoplasia · doi:10.1016/j.neo.2018.01.012 · Cited by 17
“Activating BRAF mutations appear early in melanoma development, mostly at the premalignant nevus [7], and cause constitutive activation of the MAPK pathway.”
BackgroundDesign and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors
Ramurthy, S., Costales, A., Jansen, J. M., Levine, B. H., Renhowe, P. A., Shafer, C. M., & Subramanian, S. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.12.112 · Cited by 17
Ko, T., Sharma, R., & Li, S. (2019) · Oncogene · doi:10.1038/s41388-019-1022-0 · Cited by 19
“(~82%) present in the precancerous skin melanocytic nevi, which are growth arrested and display classical hallmarks of cellular senescence [14, 15].”
BackgroundStreubel, A., Stenzinger, A., Stephan-Falkenau, S., Kollmeier, J., Misch, D., Blum, T. G., Bauer, T. T., Landt, O., Ende, A. A., Schirmacher, P., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27183 · Cited by 20
“Val600Glu mutations in benign naevi are examples that low frequency variants can be present in cfDNA also from healthy individuals [22].”
BackgroundMOB3A Bypasses BRAF and RAS Oncogene-Induced Senescence by Engaging the Hippo Pathway
Dutchak, K., Garnett, S., Nicoll, M., de Bruyns, A., & Dankort, D. L. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0767 · Cited by 19
Liu, H., Li, Z., Wang, Y., Feng, Q. F., Si, L., Cui, C., Guo, J., & Xue, W. (2014) · Pathology International · doi:10.1111/pin.12215 · Cited by 17
Emley, A., Yang, S., Wajapeyee, N., Green, M. R., & Mahalingam, M. (2009) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2009.01433.x · Cited by 17
Cell-Free DNA as a Novel Marker in Cancer Therapy
Kato, S., & Jankú, F. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.38 · Cited by 17
Defining the Molecular Genetics of Dermoscopic Naevus Patterns
Tan, J. M., Tom, L. N., Soyer, H. P., & Stark, M. S. (2018) · Dermatology · doi:10.1159/000493892 · Cited by 20
Self-citationOvercoming Resistance to Apoptosis in Cancer Therapy
Hersey, P., Zhang, X. D., & Mhaidat, N. M. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_6 · Cited by 19
The Jak-STAT Signal Transduction Pathway in Melanoma
Nicholas, C., & Gregory, B. (2011) · InTech eBooks · doi:10.5772/18876 · Cited by 22
Differential gene expression in melanocytic nevi with the V600E BRAF mutation
Bloethner, S., Snellman, E., Bermejo, J. L., Hiripi, E., Gast, A., Thirumaran, R. K., Wellenreuther, R., Hemminki, K., & Kumar, R. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20488 · Cited by 17
“The mutations in BRAF, mainly V600E, also occur in up to 80% of melanocytic nevi (Pollock et al., 2003; Kumar et al., 2004).”
BackgroundMenzies, S. W., Greenoak, G. E., Abeywardana, C. M., Crotty, K. A., & O'Neill, M. E. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23206.x · Cited by 17
Therapeutic targets in melanoma: MAPKinase pathway
Haluska, F. G., & Ibrahim, N. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0065-x · Cited by 17
BRAF, HRAS, KRAS, NRAS and CDKN2A genes analysis in cultured melanocytes used for vitiligo treatment
Czajkowski, R. (2011) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2010.04675.x · Cited by 16
Dabrafenib for the treatment ofBRAFV600-positive melanoma: a safety evaluation
Rutkowski, P. L., & Blank, C. U. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.939954 · Cited by 20
“V600E is not sufficient for malignant transformation of melanocytes on its own [11], and it is an early oncogenic event found also at high frequency in benign nevi [12].”
BackgroundBRAF gene is not mutated in plasma cell leukemia and multiple myeloma
Bonello, L., Voena, C., Ladetto, M., Boccadoro, M., Palestro, G., Inghirami, G., & Chiarle, R. (2003) · Leukemia · doi:10.1038/sj.leu.2403116 · Cited by 16
Surgical Considerations and Systemic Therapy of Melanoma
Gamboa, A. C., Lowe, M., Yushak, M. L., & Delman, K. A. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.09.012 · Cited by 17
Juhl, A. L., Byers, T., Robinson, W. A., Morelli, J. G., & Crane, L. A. (2009) · Melanoma Research · doi:10.1097/cmr.0b013e32832e0b81 · Cited by 16
Oncogenic B-RafV600E abrogates the AKT/B-Raf/Mps1 interaction in melanoma cells
Zhang, L., Shi, R., He, C., Cheng, C., Song, B., Cui, H., Zhang, Y., Zhao, Z., Bi, Y., Yang, X., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.029 · Cited by 19
Molecular mechanisms of cellular senescence and immortalization of human cells
Kiyono, T. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.12.1623 · Cited by 19
“B-Raf or N-ras mutations are frequently found in both melanomas and nevi [35-37] and there are strong suggestions that the melanocytic nevus consists of melanocytes that have undergone OIS.”
BackgroundMochel, M. C., Hammond, M. R., Frederick, D. T., Alora-Palli, M. B., Piris, A., Flaherty, K. T., & Hoang, M. P. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.06.006 · Cited by 17
Xi, Y., Riker, A. I., Shevde‐Samant, L., Samant, R. S., Morris, C. G., Gavin, E. J., Fodstad, Ø., & Ju, J. (2008) · PubMed · Cited by 16
Melanocytic Skin Neoplasms: What Lesson From Genomic Aberrations?
Urso, C. (2019) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001341 · Cited by 16
“However, provisionally, some genomic classes of neoplasms begin to appear recognizable, including: (1) melanocytic neoplasms characterized by ALK, ROS1, NTRK1, RET, MET, and NTRK3 fusions, which morphologically show large spindle and/or epithelioid cells (Spitzoid neoplasms); (2) melanocytic neoplasms characterized by…”
Background
Metadata
- Authors
- Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., & Meltzer, P. S.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- The University of Western Australia (AU)
- Corresponding author
- Meltzer, Paul S.
- ORCID
- Venue
- Nature Genetics
- Published
- 2002-11-25
- Volume
- 33
- Issue
- 1
- Pages
- 19-20
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1565041471
- Cited by
- 1,730
- References
- 4
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 40 · 2023: 49 · 2022: 46 · 2021: 73 · 2020: 58 · 2019: 73 · 2018: 67 · 2017: 87 · 2016: 79 · 2015: 87 · 2014: 84 · 2013: 104 · 2012: 92
- FWCI
- 25.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- BRAF mutation, melanocytic nevi, melanoma, melanoma metastasis, RAS/MAPK pathway, carcinogenesis
- MeSH terms
- Cell Transformation, Neoplastic, DNA Mutational Analysis, Gene Frequency, Humans, Melanoma, Nevus, Signal Transduction, Polymerase Chain Reaction, Genetic Predisposition to Disease, Mutation, Missense, Oncogene Proteins v-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.